Trillium Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics

TRIL 20.09

-0.4%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

The Dodgy Ticker

To: Miljenko Zuanic who wrote (213)	10/3/2018 8:00:55 PM
From: A.J. Mullen	1 Recommendation of 294

Back in May you were skeptical that the combination therapies they were testing would be very successful. The stock had already had a fantastic and deserved run with Cabozantanib for renal and thyroid cancer. I had sold most of my position, but was holding on to some. It's gone nowhere since then - fallen slightly. A good friend of mine took it as part of a trial for advanced prostate cancer. He was quickly kicked off the trial because the disease progressed, but he told the doctor he felt much better on the drug. The doctor agreed to continue him on it under compassionate use. My friend felt it gave him an extra two years of useful life. I'm telling the story in case we forget the human stories enmeshed in the science and business. Ashley

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next